Genomic Testing

IMPACT: Matching Treatment and Molecular Testing Extends Survival in Advanced Cancer

Wayne Kuznar

August 2018, Vol 8, No 8 - Genomic Testing

A new retrospective analysis presented at ASCO 2018 lends support to precision medicine in cancer. In the Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT) clinical trial, selecting a targeted therapy based on patients’ tumor molecular analyses independently predicted longer overall survival (OS) compared with nonmatched therapy across a diverse set of advanced tumor types. Apostolia Maria Tsimberidou, MD, PhD, Professor, Department of Investigational Cancer Therapeutics, M.D. Anderson Cancer Center, Houston, presented the study results. [ Read More ]

Next-Generation Sequencing More Cost-Effective Than Single-Gene Testing

Phoebe Starr

August 2018, Vol 8, No 8 - Genomic Testing

Genomic testing is now the standard of care for patients with non–small-cell lung cancer (NSCLC). The 4 identified genomic mutations that are targetable with FDA-approved therapies include EGFR, ALK, ROS1, and BRAF, and other NSCLC-associated genetic mutations are targetable with therapies currently being investigated in clinical trials. More genetic mutations are linked to NSCLC, but there is currently no accepted standard for genomic testing in NSCLC, or the optimal timing of such tests. [ Read More ]